It is not complicated for the clinician to diagnose a patient with advanced fibrosis or liver cirrhosis when he has already presented some decompensation of his liver disease.However,it is in the earliest stages when ...It is not complicated for the clinician to diagnose a patient with advanced fibrosis or liver cirrhosis when he has already presented some decompensation of his liver disease.However,it is in the earliest stages when the patient's prognosis can be modified the most.Since liver disease is generally asymptomatic,not invasive markers are of great relevance.In the era of omics,it is time for metabolomics to accompany genomics and proteomics,which are more established in the diagno-stics and prognostics clinical toolbox.Metabolomics,understood as the compre-hensive evaluation of the metabolites present in the organism in a specific phys-iological situation,has undoubted advantages in the study and identification of serum markers relevant to a specific pathology.Last year,I read with interest two articles published in this journal:“Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet”by Dai et al and“Metabolomics in chronic hepatitis C:Decoding fibrosis grading and underlying pathways”by Ferrasi et al.Both papers illuminate the power of metabolomics to provide us with new tools in the management of liver disease.In this editorial,I comment on these studies and others,and note how they can contribute to our understanding of liver disease in more than one way.展开更多
The severe acute respiratory syndrome-coronavirus-2(commonly known as SARS-CoV-2)is a novel coronavirus(designated as 2019-nCoV),which was isolated for the first time after the Chinese health authorities reported a cl...The severe acute respiratory syndrome-coronavirus-2(commonly known as SARS-CoV-2)is a novel coronavirus(designated as 2019-nCoV),which was isolated for the first time after the Chinese health authorities reported a cluster of pneumonia cases in Wuhan,China in December 2019.Optimal management of the Coronavirus Disease-2019 disease is evolving quickly and treatment guidelines,based on scientific evidence and experts’opinions with clinical experience,are constantly being updated.On January 30,2020,the World Health Organization declared the SARS-CoV-2 outbreak as a"Public Health Emergency of International Concern".The total lack of immune protection brought about a severe spread of the contagion all over the world.For this reason,diagnostic tools,patient management and therapeutic approaches have been tested along the way,in the desperate race to break free from the widespread infection and its fatal respiratory complications.Current medical knowledge and research on severe and critical patients’management and experimental treatments are still evolving,but several protocols on minimizing risk of infection among the general population,patients and healthcare workers have been approved and diffused by International Health Authorities.展开更多
文摘It is not complicated for the clinician to diagnose a patient with advanced fibrosis or liver cirrhosis when he has already presented some decompensation of his liver disease.However,it is in the earliest stages when the patient's prognosis can be modified the most.Since liver disease is generally asymptomatic,not invasive markers are of great relevance.In the era of omics,it is time for metabolomics to accompany genomics and proteomics,which are more established in the diagno-stics and prognostics clinical toolbox.Metabolomics,understood as the compre-hensive evaluation of the metabolites present in the organism in a specific phys-iological situation,has undoubted advantages in the study and identification of serum markers relevant to a specific pathology.Last year,I read with interest two articles published in this journal:“Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet”by Dai et al and“Metabolomics in chronic hepatitis C:Decoding fibrosis grading and underlying pathways”by Ferrasi et al.Both papers illuminate the power of metabolomics to provide us with new tools in the management of liver disease.In this editorial,I comment on these studies and others,and note how they can contribute to our understanding of liver disease in more than one way.
文摘The severe acute respiratory syndrome-coronavirus-2(commonly known as SARS-CoV-2)is a novel coronavirus(designated as 2019-nCoV),which was isolated for the first time after the Chinese health authorities reported a cluster of pneumonia cases in Wuhan,China in December 2019.Optimal management of the Coronavirus Disease-2019 disease is evolving quickly and treatment guidelines,based on scientific evidence and experts’opinions with clinical experience,are constantly being updated.On January 30,2020,the World Health Organization declared the SARS-CoV-2 outbreak as a"Public Health Emergency of International Concern".The total lack of immune protection brought about a severe spread of the contagion all over the world.For this reason,diagnostic tools,patient management and therapeutic approaches have been tested along the way,in the desperate race to break free from the widespread infection and its fatal respiratory complications.Current medical knowledge and research on severe and critical patients’management and experimental treatments are still evolving,but several protocols on minimizing risk of infection among the general population,patients and healthcare workers have been approved and diffused by International Health Authorities.
